Kelleni’s protocol incorporating non-steroidal anti-inflammatory drugs and nitazoxanide to early manage dengue virus disease: An antiviral silver bullet

Core Tip

Core Tip: Dengue virus disease (DVD) is estimated to affect up to 400 million people globally every year. The World Health Organization considers it the fastest growing mosquito-borne infection, and recently the infection has surpassed its historic transmission area. Unfortunately, there is no approved specific antiviral therapy to manage it. In this article, we argue that non-steroidal anti-inflammatory drugs and Kelleni's antiviral protocol could be easily repurposed to manage early DVD and prevent its progression to dengue hemorrhagic fever and death, as it has done with severe acute respiratory syndrome coronavirus 2 and other viruses. Kelleni's protocol has proven to be life-saving for patients of all ages in real-world practice, and it could be seen as an ideal empiric broad-spectrum antiviral Holy Grail that is much needed in our clinical practice.